Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DMAC NASDAQ:IPSC NASDAQ:KRRO NASDAQ:NMRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMACDiaMedica Therapeutics$7.09-2.6%$5.19$3.19▼$7.49$366.48M1.4429,682 shs418,976 shsIPSCCentury Therapeutics$0.50-3.4%$0.55$0.34▼$1.86$43.26M1.78600,457 shs309,742 shsKRROKorro Bio$30.76-10.6%$19.29$10.29▼$98.00$288.84M2.66234,697 shs237,420 shsNMRANeumora Therapeutics$1.62-2.4%$1.65$0.61▼$17.19$262.36M2.92338,943 shs440,408 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMACDiaMedica Therapeutics0.00%+15.47%+17.58%+101.99%+57.56%IPSCCentury Therapeutics0.00%-0.77%-10.86%-13.66%-68.70%KRROKorro Bio0.00%-7.29%+51.83%+130.76%-25.75%NMRANeumora Therapeutics0.00%-3.57%-0.61%+87.59%-86.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMACDiaMedica Therapeutics$7.09-2.6%$5.19$3.19▼$7.49$366.48M1.4429,682 shs418,976 shsIPSCCentury Therapeutics$0.50-3.4%$0.55$0.34▼$1.86$43.26M1.78600,457 shs309,742 shsKRROKorro Bio$30.76-10.6%$19.29$10.29▼$98.00$288.84M2.66234,697 shs237,420 shsNMRANeumora Therapeutics$1.62-2.4%$1.65$0.61▼$17.19$262.36M2.92338,943 shs440,408 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMACDiaMedica Therapeutics0.00%+15.47%+17.58%+101.99%+57.56%IPSCCentury Therapeutics0.00%-0.77%-10.86%-13.66%-68.70%KRROKorro Bio0.00%-7.29%+51.83%+130.76%-25.75%NMRANeumora Therapeutics0.00%-3.57%-0.61%+87.59%-86.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDMACDiaMedica Therapeutics 3.00Buy$12.3373.95% UpsideIPSCCentury Therapeutics 3.00Buy$3.75648.80% UpsideKRROKorro Bio 3.29Buy$86.83182.29% UpsideNMRANeumora Therapeutics 2.22Hold$7.14340.92% UpsideCurrent Analyst Ratings BreakdownLatest IPSC, KRRO, DMAC, and NMRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025DMACDiaMedica TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.008/13/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/13/2025KRROKorro BioRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetStrong-Buy$153.00 ➝ $147.008/13/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$100.00 ➝ $90.007/24/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.007/18/2025DMACDiaMedica TherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $14.007/18/2025DMACDiaMedica TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $11.007/18/2025DMACDiaMedica TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $12.007/16/2025NMRANeumora TherapeuticsMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$4.00 ➝ $5.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDMACDiaMedica TherapeuticsN/AN/AN/AN/A$0.95 per shareN/AIPSCCentury Therapeutics$6.59M6.57N/AN/A$1.90 per share0.26KRROKorro Bio$2.27M127.24N/AN/A$17.12 per share1.80NMRANeumora TherapeuticsN/AN/AN/AN/A$1.78 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDMACDiaMedica Therapeutics-$24.44M-$0.69N/AN/AN/AN/A-78.99%-69.94%11/12/2025 (Estimated)IPSCCentury Therapeutics-$126.57M-$0.29N/AN/AN/A-19.10%-11.53%-6.94%11/4/2025 (Estimated)KRROKorro Bio-$83.58M-$9.75N/AN/AN/AN/A-61.51%-42.87%11/11/2025 (Estimated)NMRANeumora Therapeutics-$243.79M-$1.57N/AN/AN/AN/A-98.95%-87.68%11/11/2025 (Estimated)Latest IPSC, KRRO, DMAC, and NMRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025IPSCCentury Therapeutics-$0.38-$0.38N/A-$0.38$0.03 millionN/A8/12/2025Q2 2025DMACDiaMedica Therapeutics-$0.18-$0.18N/A-$0.18N/AN/A8/12/2025Q2 2025KRROKorro Bio-$2.54-$2.74-$0.20-$2.74$0.41 million$1.46 million8/6/2025Q2 2025NMRANeumora Therapeutics-$0.38-$0.33+$0.05-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDMACDiaMedica TherapeuticsN/A7.557.55IPSCCentury TherapeuticsN/A10.7210.72KRROKorro BioN/A5.985.98NMRANeumora Therapeutics0.1110.5410.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDMACDiaMedica Therapeutics10.12%IPSCCentury Therapeutics50.20%KRROKorro Bio13.18%NMRANeumora Therapeutics47.65%Insider OwnershipCompanyInsider OwnershipDMACDiaMedica Therapeutics7.30%IPSCCentury Therapeutics5.00%KRROKorro Bio4.60%NMRANeumora Therapeutics26.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDMACDiaMedica Therapeutics2051.69 million47.92 millionOptionableIPSCCentury Therapeutics17086.39 million82.07 millionOptionableKRROKorro Bio709.39 million8.96 millionNo DataNMRANeumora Therapeutics108161.95 million118.54 millionOptionableIPSC, KRRO, DMAC, and NMRA HeadlinesRecent News About These CompaniesNeumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $7.14 Average Price Target from AnalystsSeptember 12 at 2:33 AM | americanbankingnews.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by AnalystsSeptember 11, 2025 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Short Interest Down 26.3% in AugustSeptember 10, 2025 | marketbeat.comNuveen LLC Takes $221,000 Position in Neumora Therapeutics, Inc. $NMRASeptember 8, 2025 | marketbeat.comGraham Capital Management L.P. Has $1.16 Million Holdings in Neumora Therapeutics, Inc. $NMRASeptember 6, 2025 | marketbeat.comNeumora Therapeutics to Participate in Upcoming Conferences in SeptemberSeptember 2, 2025 | globenewswire.comT. Rowe Price Investment Management Inc. Sells 2,899,770 Shares of Neumora Therapeutics, Inc. $NMRAAugust 27, 2025 | marketbeat.comNeumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861August 20, 2025 | msn.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Hold" by AnalystsAugust 16, 2025 | marketbeat.comNeumora Therapeutics, Inc.: Promising Potential in Obesity Therapeutics with NMRA-215August 7, 2025 | tipranks.comNeumora outlines six upcoming clinical catalysts and prioritizes obesity program with NMRA-215August 7, 2025 | msn.comNeumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | seekingalpha.comNeumora Therapeutics Reports Q2 2025 Financial ResultsAugust 7, 2025 | tipranks.comNeumora Therapeutics reports Q2 EPS (33c), consensus (37c)August 6, 2025 | msn.comNeumora (NMRA) Q2 Loss Improves 10%August 6, 2025 | aol.comANeumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 6, 2025 | globenewswire.comMizuho Raises Price Target for Neumora (NMRA), Keeps Outperform RatingJuly 30, 2025 | msn.com5 Alzheimer’s Readouts To WatchJuly 28, 2025 | biospace.comBNeumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025July 23, 2025 | globenewswire.comMizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform RatingJuly 20, 2025 | finance.yahoo.comNeumora Therapeutics, Inc.: Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861July 10, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPSC, KRRO, DMAC, and NMRA Company DescriptionsDiaMedica Therapeutics NASDAQ:DMAC$7.09 -0.19 (-2.61%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.20 +0.11 (+1.55%) As of 05:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Century Therapeutics NASDAQ:IPSC$0.50 -0.02 (-3.38%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.51 +0.01 (+1.84%) As of 05:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Korro Bio NASDAQ:KRRO$30.76 -3.63 (-10.56%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$31.52 +0.76 (+2.46%) As of 04:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Neumora Therapeutics NASDAQ:NMRA$1.62 -0.04 (-2.41%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.62 +0.00 (+0.31%) As of 06:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
